Clinical outcome of patients with TP53 AML treated with non-intensive vidaza-venetoclax chemotherapy : Venaura retrospective regional multicenter study.
Retrospective analysis shows survival linked to TP53 mutations in AML patients treated with azacitidine and venetoclax.
Key Points
Overall survival in the cohort was 7.4 months, revealing the challenges of TP53-mutated acute myeloid leukemia treatment.
The complete remission combined rate was 54%, underscoring the potential of azacitidine and venetoclax in managing this high-risk patient group.
Data were gathered from the VENAURA registry comprising 755 cases across 10 centers in France, analyzing treatment response and factors affecting outcomes regarding TP53 mutations.
The findings highlight the prognostic value of performance status and mutation profile in predicting survival among patients with TP53 mutations in acute myeloid leukemia.
Cite This Study
Tauveron-Jalenques et al. (2025) studied this question.